Florent Eymard

Prof. Dr. Florent Eymard

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2017 in Journal of Orthopaedic Research
Verified
Journal Article
Closed access
PDF file
FEFlorent Eymard
Florent Eymard
XCXavier Chevalier
Xavier Chevalier
TCThierry Conrozier
Thierry Conrozier

6 January 2017 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
ORon behalf of the Osteoarthritis Group of the French Society of Rheumatology and of the French Research Group in Interventional Rheumatology
on behalf of the Osteoarthritis Group of the French Society of Rheumatology and of the French Research Group in Interventional Rheumatology
FEFlorent Eymard
Florent Eymard
BMBernard Maillet
Bernard Maillet
HLHenri Lellouche
Henri Lellouche
SMSylvie Mellac-Ducamp
Sylvie Mellac-Ducamp
TCThierry Conrozier
Thierry Conrozier
To identify predictive factors of response to viscosupplementation (VS) in patients with hip osteoarthritis (HOA). Prospective, multicentre, open-label trial, achieved in daily practice conditions. Patients with HOA were treated with a single intra-articular injection of a cross-linked hyaluronic acid combined with mannitol (HAnox-M-XL), using imaging guidance. WOMAC pain and function scores and patient global assessment (PGA) were assessed at baseline and day 90. Improvement, satisfaction and efficacy were self-assessed at day 90. Hip radiographs at baseline were scored using Kellgren-Lawrence grade and Osteoarthritis Research Society International (OARSI) score. Associations between clinical and radiological features and response to VS (pain improvement > 50% at day 90) were assessed in univariate analysis, and then using logistic regression, adjusted for confounding factors. The intent-to-treat (ITT) population included 97 patients (57 females, mean age 63). Ninety completed the follow-up and 80 had full clinical and radiological data. Response to VS was achieved in 47.8% of patients. In univariate analysis, the only clinical outcome statistically and negatively related to response was PGA at baseline (p = 0.047). Radiologically, response to VS was negatively correlated with joint space narrowing (JSN) score (JSN < 2 vs. JSN ≥ 2, p = 0.01) and was related to the patterns of femoral head migration (p = 0.008). In multivariate analysis, only JSN grade (p = 0.03) remained significantly related to a poor response. This pilot study, which needs further confirmation by larger scale trials, suggests that radiological features might be of importance for the decision of VS in patients with HOA. ID RCB N°2013-A00165-40. Registered 31 January 2013.

Verified
Journal Article
Open access
PDF file
SBSabryne Berkani
Sabryne Berkani
ACAlice Courties
Alice Courties
FEFlorent Eymard
Florent Eymard
ALAugustin Latourte
Augustin Latourte
PRPascal Richette
Pascal Richette
KLKarine Louati
Karine Louati
Intra-articular (IA) hyaluronic acid (HA) and platelet-rich plasma (PRP) injections are increasingly being prescribed for knee osteoarthritis (KOA). However, failure of the medical treatment may result in total knee arthroplasty (TKA). We wondered if IA HA or PRP injections (intervention) may delay the time to TKA (outcome) among KOA patients (population), compared to KOA patients not receiving these injections (comparator). For this systematic literature review (SLR) and meta-analysis, we selected observational studies with at least one group of patients receiving IA HA or PRP and with TKA data available. The main outcome was time from the diagnosis of KOA to TKA. We included 25 articles in the SLR (2,824,401 patients) and four in the meta-analysis. The mean strengthening the reporting of observational studies in epidemiology (STROBE) score was 63%. For patients receiving versus not receiving HA injections, the delay between a declared diagnosis of KOA to TKA was increased by 9.8 months (95% CI (8.2–11.4)). As compared with standard of care, the effect size of HA injections for this outcome was 0.57 (95% CI (0.36–0.76)). Only one study described a median time from PRP injections to TKA of 4.1 years (range 0.3–14.7). IA HA injections were associated with increased time to TKA. Causality cannot be concluded because of missing confounder factors as comorbidities. Data were insufficient to conclude any effect of PRP injections on TKA delay.

22 April 2025 in Knee Surgery, Sports Traumatology, Arthroscopy
Verified
Journal Article
Open access
FEFlorent Eymard
Florent Eymard
KLKarine Louati
Karine Louati
ÉNÉric Noel
Éric Noel
RARedouane Abouqal
Redouane Abouqal
PAPhilippe Adam
Philippe Adam
HBHervé Bard
Hervé Bard
Purpose: Platelet‐rich plasma (PRP) could be a vector for certain diseases, and its composition may vary by pathologic condition. The main comorbidities that could affect PRP composition are infectious, oncologic and haematologic. In addition to potential alteration of clinical response, these pathologies could have a significant impact on the local tolerance of PRP as well as a risk of disease dissemination to the injection site. To date, there are few specific recommendations related to these comorbidities to guide clinicians. Therefore, the International Research Group on Platelet Injections (GRIIP) supported a consensus project to develop these recommendations. Methods: Following the ‘recommendations by formal consensus’ methodology, a steering committee performed a literature review and drafted an initial set of recommendations. They were evaluated by an international rating group (15 specialists in musculoskeletal [MSK] diseases, five haematologists, four oncologists, three infectiologists and four scientists specialising in platelet physiology). From this rating, the first set of recommendations was discussed in a plenary meeting and then modified by the steering committee. Finally, four overarching principles and 23 recommendations were re‐evaluated by the rating group. Recommendations were classified as appropriate or not, with strong or relative agreement, or uncertain. Results: From the 23 recommendations, 10 concerned infectious diseases (viral and bacterial infections; dialysis; immunosuppressive drugs; dental care…), five oncologic diseases (local tumour; cured, active or in remission cancer…) and eight haematologic diseases (cytopenia; cured, active or stabilised cured hemopathy; monoclonal gammopathy…). All were considered appropriate by the experts (median = 9; range = 8–9), with strong or relative agreement. Due to the paucity of literature data, the recommendations are mainly based on expert opinion (Grade D). Conclusion: This consensus project provides four overarching principles and 23 recommendations related to contraindications of PRP injections in case of infectious, oncologic or hematologic diseases, validated by an international expert group. Level of Evidence: Level I.

1 December 2020 in Revue du Rhumatisme
Verified
Journal Article
Closed access
JSJérémie Sellam
Jérémie Sellam
ACAlice Courties
Alice Courties
FEFlorent Eymard
Florent Eymard
SFStéphanie Ferrero
Stéphanie Ferrero
ALAugustin Latourte
Augustin Latourte
PRPascal Richette
Pascal Richette

5 November 2025 in Regenerative Therapy
Verified
Journal Article
Open access
IAIsabel Andia
Isabel Andia
ASAlain Silvestre
Alain Silvestre
CACristina Del Amo
Cristina Del Amo
FEFlorent Eymard
Florent Eymard
HBHervé Bard
Hervé Bard
Platelet-rich plasma (PRP) is now one of the most widely used orthobiologics in musculoskeletal medicine, with knee osteoarthritis (KOA) as its main indication. PRP represents a spectrum of autologous preparations with differing cellular and protein content. In this narrative review, we frame current knowledge as a "research ecosystem" spanning mechanistic biology, product characterization, randomized controlled trials (RCTs), systematic reviews and meta-analyses, methodological evaluations, expert consensus, and precision medicine. We highlight the diverse biological roles of PRP components, including the immunomodulatory activity of platelets, the dual regenerative and inflammatory effects of leukocytes, and emerging neutrophil-macrophage crosstalk. Advances in classification systems and deep learning-based quality control are also discussed. Across RCTs, PRP generally outperforms corticosteroids and hyaluronic acid in early to moderate KOA, with benefits lasting several months to a year. Methodological evaluation adds nuance: fragility index analysis confirmed PRP's advantage but showed individual trials were only modestly robust, while spin in systematic reviews often overstated benefits, underscoring the need for more rigorous RCTs and transparent reporting. Leukocyte and platelet concentrations do not explain outcomes, highlighting the importance of patient-specific factors such as metabolic status, inflammation, and structural phenotype. Progress remains hampered by inconsistent reporting, lack of a standardized classification system, and inadequate stratification. We propose a roadmap linking product characterization, standardized reporting, precision patient selection, and objective outcome measures, aiming to shift PRP from a generic injection toward a tailored regenerative therapy.